Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

LEXINGTON, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company ...

Researchers say lerociclib plus fulvestrant could become a new treatment option for HR+/HER2- advanced breast cancer, but lerociclib is not approved in the US.

The direct antiglobulin test was positive for anti-C3d specificity, with cold agglutinin titer confirming the diagnosis of CAD.

Two new medications, called lecanemab and donanemab, have shown success in clinical trials in slowing down Alzheimer’s disease. These are known as disease-modifying treatments and have been licensed ...

Gene therapy using modified blood stem cells helped five adults with severe hemophilia A reach therapeutic levels of clotting ...

Impact of sex on in-hospital mortality and 90-day readmissions in patients undergoing transcatheter mitral valve replacement (TMVR): Analysis from the nationwide readmission database.

Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended ...

Erba Transasia Group, India’s No. 1 In-vitro Diagnostic (IVD) Company and among the leading global IVD players focused on emerging markets, today introduced Erba H7100 – its advanced Haematology ...

Exchange Traded Concepts LLC acquired a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...